Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Receivables (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Change in Receivables for 17 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 35.0% to -$2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.2 million through Dec 2025, down 171.26% year-over-year, with the annual reading at -$6.2 million for FY2025, 171.26% down from the prior year.
  • Change in Receivables for Q4 2025 was -$2.6 million at Myriad Genetics, up from -$19.0 million in the prior quarter.
  • The five-year high for Change in Receivables was $17.5 million in Q1 2023, with the low at -$19.0 million in Q3 2025.
  • Average Change in Receivables over 5 years is $1.7 million, with a median of $50000.0 recorded in 2021.
  • The sharpest move saw Change in Receivables tumbled 1120.0% in 2022, then surged 2600.0% in 2025.
  • Over 5 years, Change in Receivables stood at -$3.0 million in 2021, then grew by 16.67% to -$2.5 million in 2022, then soared by 52.0% to -$1.2 million in 2023, then plummeted by 233.33% to -$4.0 million in 2024, then surged by 35.0% to -$2.6 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$2.6 million, -$19.0 million, and $16.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.